Current whole-body MRI applications in the neurofibromatoses
dc.contributor.author | Ahlawat, S | |
dc.contributor.author | Fayad, LM | |
dc.contributor.author | Khan, MS | |
dc.contributor.author | Bredella, MA | |
dc.contributor.author | Harris, GJ | |
dc.contributor.author | Evans, DG | |
dc.contributor.author | Farschtschi, S | |
dc.contributor.author | Jacobs, MA | |
dc.contributor.author | Chhabra, A | |
dc.contributor.author | Salamon, JM | |
dc.contributor.author | Wenzel, R | |
dc.contributor.author | Mautner, VF | |
dc.contributor.author | Dombi, E | |
dc.contributor.author | Cai, W | |
dc.contributor.author | Plotkin, SR | |
dc.contributor.author | Blakeley, JO | |
dc.contributor.author | Hanemann, Clemens Oliver | |
dc.date.accessioned | 2016-10-12T12:52:52Z | |
dc.date.available | 2016-10-12T12:52:52Z | |
dc.date.issued | 2016-08-16 | |
dc.identifier.issn | 0028-3878 | |
dc.identifier.issn | 1526-632X | |
dc.identifier.uri | http://hdl.handle.net/10026.1/6502 | |
dc.description.abstract |
OBJECTIVES: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials. METHODS: A systematic process was used to review all published data about WB-MRI in NF syndromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific techniques for assessment of tumor burden, characterization of neoplasms, and response to therapy. RESULTS: WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR) sequence is used in all investigations to date, suggesting consensus about the utility of this sequence for detection of WB tumor burden in people with NF. There are insufficient data to support a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches. Functional imaging, although used in some NF studies, has not been systematically applied or evaluated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI reproducibility. CONCLUSIONS: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The STIR sequence is a core sequence. Additional investigation is needed to define the optimal approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic performance of WB-MRI vs regional MRI. | |
dc.format.extent | S31-S39 | |
dc.format.medium | ||
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Ovid Technologies (Wolters Kluwer Health) | |
dc.subject | Clinical Trials as Topic | |
dc.subject | Humans | |
dc.subject | Magnetic Resonance Imaging | |
dc.subject | Multicenter Studies as Topic | |
dc.subject | Neurilemmoma | |
dc.subject | Neurofibromatoses | |
dc.subject | Neurofibromatosis 1 | |
dc.subject | Neurofibromatosis 2 | |
dc.subject | Skin Neoplasms | |
dc.subject | Whole Body Imaging | |
dc.title | Current whole-body MRI applications in the neurofibromatoses | |
dc.type | journal-article | |
dc.type | Consensus Development Conference | |
dc.type | Journal Article | |
dc.type | Practice Guideline | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000382328100006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 7 Supplement 1 | |
plymouth.volume | 87 | |
plymouth.publication-status | Published | |
plymouth.journal | Neurology | |
dc.identifier.doi | 10.1212/WNL.0000000000002929 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
plymouth.organisational-group | /Plymouth/Users by role/Researchers in ResearchFish submission | |
dc.publisher.place | United States | |
dcterms.dateAccepted | 2016-05-26 | |
dc.rights.embargodate | 2017-8-15 | |
dc.identifier.eissn | 1526-632X | |
dc.rights.embargoperiod | No embargo | |
rioxxterms.versionofrecord | 10.1212/WNL.0000000000002929 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2016-08-16 | |
rioxxterms.type | Journal Article/Review |